Page 18 - Read Online

Page 14 of 17 Testa et al. J Cancer Metastasis Treat 2020;6:53 I http://dx.doi.org/10.20517/2394-4722.2020.111

also play an essential role in the development of leukemia and growing evidence shows that targeting of
both leukemic endothelium and leukemic stem cells represents a more effective antileukemic therapeutic
strategy.

Bone marrow angiogenesis is enhanced in many patients with AML and several studies have shown a
link between some leukemic-specific genetic alterations and stimulation of bone marrow angiogenesis.
A better understanding of angiogenesis in AMLs may contribute both to a better understanding of the
leukemogenetic process and to define an improved strategy for the treatment of these leukemias.

DECLARATIONS
Authors’ contributions
Made substantial contributions to conception, design of the study and analysis and interpretation of the
literature data: Testa U, Castelli G, Pelosi E
Contributed to the preparation of the manuscript and to the supervision of all data included in this
manuscript: Testa U

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
©The Author(s) 2020.

REFERENCES
1. Eelen G, Treps L, Carmeliet P. Basic and therapeutic aspects of angiogenesis updated. Circ Res 2020;127:310-29.
2. Ribatti D, Vacca A, Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999;1:293-302.
3. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth
factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356-61.
4. Ribatti D. Is angiogenesis essential for the progression of hematological malignancies or is it an epiphenomenon? Leukemia 2009;23:433-4.
5. Testa U, Saulle E, Castelli G, Pelosi E. Endothelial progenitor cells in hematological malignancies. Stem Cell Invest 2016;3:26.
6. Marcu R, Choi YJ, Xue J, et al. Human organ-specific endothetial cell heterogeneity. IScience 2018;4:20-35.
7. Qiu J, Hirschi KK. Endothelial cell development and its application to regenerative medicine. Circulation Res 2019;125:489-501.
8. Plein A, Fantin A, Denti L, Pollard JW, Ruhberg C. Erythro-myeloid progenitors contribute endothelial cells to blood vessels. Nature
2018;562:223-8.
9. McDonald AI, Shirali AS, Aragon R, et al. Endothelial regeneration of large vessels is a biphasic process driven by local cells with
distinct proliferative capacities. Cell Stem Cell 2018;23:210-25.
10. Wakabayashi T, Naito H, Suehiro JI, et al. CD157 marks tissue-resident endothelial stem cells with homeostatic and regenerative
properties. Cell Stem Cell 2018;22:384-97.
11. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nature Med 2011;17:1359-69.
12. Testa U, Pelosi E, Castelli G. Endothelial progenitors in the tumor microenvironment. Adv Exp Med Biol 2020;1263:85-115.
13. Kumar S, Sharife H, Kreisel T, et al. Intra-tumoral metabolic zonation and resultant phenotypic diversification are dictated by blood